MY DEAR FRIEND AND E-PAL DR. JOHN ABELES IS FOUNDER AND CHAIRMAN OF NEUROTROPE, INC. RSK
www.neurotropebioscience.com
Neurotrope BioScience is collaborating with the Blanchette Rockefeller Neuroscience Institute (BRNI) to advance novel diagnostic and therapeutic technologies developed at BRNI that have shown exceptional promise in both preclinical and clinical models of Alzheimer’s Disease. The commercial introduction of a new, non-invasive diagnostic test for early stage Alzheimer’s Disease is the first milestone this collaboration seeks to achieve. Following this, the BRNI-Neurotrope BioScience team plans on initiating several Phase 2 clinical trials in this disease with novel drug prototypes discovered at BRNI.
The research team at BRNI has pioneered a new approach to treat neurodegenerative disease through the activation of protein kinase C-epsilon (PKCε). While the inhibition of PKC has previously been explored in clinical studies for the treatment of cancer, BRNI has discovered the selective activation of this enzyme is effective in treating memory and cognition disorders stemming from neurodegenerative disease. This approach exploits a complex pathway of biochemical events in the neuron that seem to be centrally orchestrated by PKCε. The changes mediated by PKCε effectively converge in reversing the neuronal damage and loss central to the pathogenic process in Alzheimer’s Disease.